GliaXTM platform

GliaPharm has developed a proprietary technology platform, GliaXTM, to identify drugs that target glial cells’ activity and brain energy metabolism.

GliaXTM includes:

  • Proprietary high throughput screening (HTS) technologies based on enzymatic and primary cell activities.
  • A number of metabolic tests to characterize compounds in vitro (primary brain cells cultures) and in vivo (rodent’s brain).
  • Different rodent models of neurological pathologies, including brain ageing, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and several psychiatric diseases.
  • Different additional aspects of drug development and regulation are performed through selective contract research organizations (CROs).

GliaXTM platform not only serves GliaPharm’s in-house drug development, but is also used through collaborations with academic and industrial partners.